Comparison between nafarelin acetate and D-Trp6-LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: a prospective crossover study.

Tanos V, Friedler S, Shushan A, Strauss N, Hetsroni I, Lewin A

Journal of assisted reproduction and genetics1 Nov 1995Cited by 2 (Europe PMC)

PMID8624429DOI10.1007/bf02212899PepBankPUB-08624429

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In IVF patients, nafarelin and D-Trp6-LHRH achieved estradiol suppression at equal time intervals.
In plain wordsIn IVF patients, nafarelin and D-Trp6-LHRH took the same time to suppress estrogen.
Peptide
Nafarelin
Outcome
No significant changeTime to estradiol suppression
Study
n = 40
Comparator
D-Trp6-LHRH 0.5 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
600 micrograms dailyAs given in this study (human).
Source sentences
Summary
Estradiol suppression was achieved by both D-Trp6-LHRH and nafarelin at equal time intervals.
3 context sentences(design, population, supporting numbers)
Summary · context
A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol.
Summary · context
Twenty patients used nafarelin acetate 600 micrograms/daily in their first cycle and received D-Trp6-LHRH, 0.5 mg/daily, in their following cycle.
Summary · context
The other 20 women used decapeptyl in their cycle and received nafarelin in the second.
Report a problemFND-0862442901
02HumanNon-randomized trialEfficacy outcome
In IVF patients, nafarelin cycles required significantly fewer hMG ampoules than D-Trp6-LHRH cycles (P = 0.0005).
In plain wordsIn IVF patients, nafarelin cycles required fewer hMG ampoules than D-Trp6-LHRH cycles.
Peptide
Nafarelin
Outcome
DecreaseTotal hMG ampoules
Study
n = 40
Comparator
D-Trp6-LHRH 0.5 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
600 micrograms dailyAs given in this study (human).
Source sentences
Summary
The average total number of ampoules (P = 0.0005) and the length of administration of hMG required for ovarian stimulation (P = 0.0002) and the time interval between GnRHa initiation to oocyte retrieval (P = 0.04) was significantly lower in nafarelin cycles.
3 context sentences(design, population, supporting numbers)
Summary · context
A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol.
Summary · context
Twenty patients used nafarelin acetate 600 micrograms/daily in their first cycle and received D-Trp6-LHRH, 0.5 mg/daily, in their following cycle.
Summary · context
The other 20 women used decapeptyl in their cycle and received nafarelin in the second.
Report a problemFND-0862442902
03HumanNon-randomized trialEfficacy outcome
In IVF patients, hMG administration was significantly shorter in nafarelin cycles than D-Trp6-LHRH cycles (P = 0.0002).
In plain wordsIn IVF patients, hMG treatment was shorter in nafarelin cycles than D-Trp6-LHRH cycles.
Peptide
Nafarelin
Outcome
DecreasehMG administration duration
Study
n = 40
Comparator
D-Trp6-LHRH 0.5 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
600 micrograms dailyAs given in this study (human).
Source sentences
Summary
The average total number of ampoules (P = 0.0005) and the length of administration of hMG required for ovarian stimulation (P = 0.0002) and the time interval between GnRHa initiation to oocyte retrieval (P = 0.04) was significantly lower in nafarelin cycles.
3 context sentences(design, population, supporting numbers)
Summary · context
A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol.
Summary · context
Twenty patients used nafarelin acetate 600 micrograms/daily in their first cycle and received D-Trp6-LHRH, 0.5 mg/daily, in their following cycle.
Summary · context
The other 20 women used decapeptyl in their cycle and received nafarelin in the second.
Report a problemFND-0862442903
04HumanNon-randomized trialEfficacy outcome
In IVF patients, time from GnRHa initiation to oocyte retrieval was significantly shorter with nafarelin than D-Trp6-LHRH (P = 0.04).
In plain wordsIn IVF patients, the interval from treatment initiation to egg retrieval was shorter with nafarelin than D-Trp6-LHRH.
Peptide
Nafarelin
Outcome
DecreaseTime from GnRHa initiation to oocyte retrieval
Study
n = 40
Comparator
D-Trp6-LHRH 0.5 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
600 micrograms dailyAs given in this study (human).
Source sentences
Summary
The average total number of ampoules (P = 0.0005) and the length of administration of hMG required for ovarian stimulation (P = 0.0002) and the time interval between GnRHa initiation to oocyte retrieval (P = 0.04) was significantly lower in nafarelin cycles.
3 context sentences(design, population, supporting numbers)
Summary · context
A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol.
Summary · context
Twenty patients used nafarelin acetate 600 micrograms/daily in their first cycle and received D-Trp6-LHRH, 0.5 mg/daily, in their following cycle.
Summary · context
The other 20 women used decapeptyl in their cycle and received nafarelin in the second.
Report a problemFND-0862442904
05HumanNon-randomized trialEfficacy outcome
In IVF patients, follicle counts, large/small follicle distribution, and average oocyte retrieval counts did not differ between nafarelin and D-Trp6-LHRH.
In plain wordsIn IVF patients, follicle counts, follicle size distribution, and egg retrieval counts did not differ between nafarelin and D-Trp6-LHRH.
Peptide
Nafarelin
Outcome
No significant changeFollicle number, size distribution, and oocytes retrieved
Study
n = 40
Comparator
D-Trp6-LHRH 0.5 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
600 micrograms dailyAs given in this study (human).
Source sentences
Summary
The number and the distribution between large and small follicles as well as the average number of oocytes retrieved did not differ between the two GnRH analogues.
3 context sentences(design, population, supporting numbers)
Summary · context
A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol.
Summary · context
Twenty patients used nafarelin acetate 600 micrograms/daily in their first cycle and received D-Trp6-LHRH, 0.5 mg/daily, in their following cycle.
Summary · context
The other 20 women used decapeptyl in their cycle and received nafarelin in the second.
Report a problemFND-0862442905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.